[
    [
        {
            "time": "",
            "original_text": "A股三季报交出优异答卷，营收净利润增速创近五年新高",
            "features": {
                "keywords": [
                    "A股",
                    "三季报",
                    "营收",
                    "净利润",
                    "增速",
                    "新高"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "全市场"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A股三季报交出优异答卷，营收净利润增速创近五年新高",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 10,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11",
            "original_text": "赵军宁任国家药品监督管理局副局长 | 新一轮国家医保谈判即将于11月开始【最新闻1101】",
            "features": {
                "keywords": [
                    "赵军宁",
                    "国家药品监督管理局",
                    "医保谈判",
                    "11月"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "赵军宁任国家药品监督管理局副局长 | 新一轮国家医保谈判即将于11月开始【最新闻1101】",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "社保基金最新路线图曝光，调仓频率加快，有色金属行业成新宠，长期持有6只利润翻倍股",
            "features": {
                "keywords": [
                    "社保基金",
                    "调仓",
                    "有色金属",
                    "利润翻倍股"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "有色金属"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "社保基金最新路线图曝光，调仓频率加快，有色金属行业成新宠，长期持有6只利润翻倍股",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "兴业证券：维持智飞生物（300122.SZ）“审慎增持”评级 业绩增长符合预期 HPV贡献有望提速",
            "features": {
                "keywords": [
                    "兴业证券",
                    "智飞生物",
                    "审慎增持",
                    "HPV",
                    "业绩增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "兴业证券：维持智飞生物（300122.SZ）“审慎增持”评级 业绩增长符合预期 HPV贡献有望提速",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "国泰君安：予智飞生物（300122.SZ）“增持”评级 目标价下调至184.68元",
            "features": {
                "keywords": [
                    "国泰君安",
                    "智飞生物",
                    "增持",
                    "目标价下调"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "国泰君安：予智飞生物（300122.SZ）“增持”评级 目标价下调至184.68元",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "西部证券给予智飞生物买入评级：自主产品销售高速增长，多款在研待上市",
            "features": {
                "keywords": [
                    "西部证券",
                    "智飞生物",
                    "买入评级",
                    "自主产品",
                    "销售增长",
                    "在研产品"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "西部证券给予智飞生物买入评级：自主产品销售高速增长，多款在研待上市",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021",
            "original_text": "智飞生物2021年三季报点评：在研产品推进顺利，新冠疫苗贡献显著业绩【东吴医药朱国广团队】",
            "features": {
                "keywords": [
                    "智飞生物",
                    "三季报",
                    "在研产品",
                    "新冠疫苗",
                    "业绩"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物2021年三季报点评：在研产品推进顺利，新冠疫苗贡献显著业绩【东吴医药朱国广团队】",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]